Nat Commun. 2024 Jan 20. 15(1): 633
Xue Zhang,
Shishir M Pant,
Cecily C Ritch,
Hsin-Yao Tang,
Hongguang Shao,
Harsh Dweep,
Yao-Yu Gong,
Rebekah Brooks,
Patricia Brafford,
Adam J Wolpaw,
Yool Lee,
Ashani Weeraratna,
Amita Sehgal,
Meenhard Herlyn,
Andrew Kossenkov,
David Speicher,
Peter K Sorger,
Sandro Santagata,
Chi V Dang.
The circadian clock regulator Bmal1 modulates tumorigenesis, but its reported effects are inconsistent. Here, we show that Bmal1 has a context-dependent role in mouse melanoma tumor growth. Loss of Bmal1 in YUMM2.1 or B16-F10 melanoma cells eliminates clock function and diminishes hypoxic gene expression and tumorigenesis, which could be rescued by ectopic expression of HIF1α in YUMM2.1 cells. By contrast, over-expressed wild-type or a transcriptionally inactive mutant Bmal1 non-canonically sequester myosin heavy chain 9 (Myh9) to increase MRTF-SRF activity and AP-1 transcriptional signature, and shift YUMM2.1 cells from a Sox10high to a Sox9high immune resistant, mesenchymal cell state that is found in human melanomas. Our work describes a link between Bmal1, Myh9, mouse melanoma cell plasticity, and tumor immunity. This connection may underlie cancer therapeutic resistance and underpin the link between the circadian clock, MRTF-SRF and the cytoskeleton.